Cin­Cor’s hy­per­ten­sion can­di­date flops a PhII test but plans to charge ahead with piv­otal study

To­ward the end of sum­mer, Mass­a­chu­setts-based Cin­Cor Phar­ma was rid­ing high with a $225 mil­lion raise, tout­ing a pos­i­tive da­ta read­out. But a clos­er look un­der the hood has re­vealed a few hic­cups in its Phase II.

Cin­Cor on Mon­day un­veiled topline re­sults from its Phase II tri­al, dubbed HA­LO, eval­u­at­ing bax­dro­stat in pa­tients with un­con­trolled hy­per­ten­sion who are tak­ing up to two blood pres­sure med­ica­tions. The tri­al whiffed on its pri­ma­ry end­point of eval­u­at­ing change from the “base­line in mean seat­ed” sys­tolic blood pres­sure (SBP) in the in­tent-to-treat pop­u­la­tion in all dosage lev­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER